1
|
Steptoe PJ, Scott JT, Baxter JM, Parkes CK, Dwivedi R, Czanner G, Vandy MJ, Momorie F, Fornah AD, Komba P, Richards J, Sahr F, Beare NAV, Semple MG. Novel Retinal Lesion in Ebola Survivors, Sierra Leone, 2016. Emerg Infect Dis 2018. [PMID: 28628441 PMCID: PMC5512503 DOI: 10.3201/eid2307.161608] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
A lesion specific to Ebola virus disease showed an anatomical distribution suggesting neuronal transmission. We conducted a case–control study in Freetown, Sierra Leone, to investigate ocular signs in Ebola virus disease (EVD) survivors. A total of 82 EVD survivors with ocular symptoms and 105 controls from asymptomatic civilian and military personnel and symptomatic eye clinic attendees underwent ophthalmic examination, including widefield retinal imaging. Snellen visual acuity was <6/7.5 in 75.6% (97.5% CI 63%–85.7%) of EVD survivors and 75.5% (97.5% CI 59.1%–87.9%) of controls. Unilateral white cataracts were present in 7.4% (97.5% CI 2.4%–16.7%) of EVD survivors and no controls. Aqueous humor from 2 EVD survivors with cataract but no anterior chamber inflammation were PCR-negative for Zaire Ebola virus, permitting cataract surgery. A novel retinal lesion following the anatomic distribution of the optic nerve axons occurred in 14.6% (97.5% CI 7.1%–25.6%) of EVD survivors and no controls, suggesting neuronal transmission as a route of ocular entry.
Collapse
|
2
|
Cooper PJ, Guderian RH, Proaño R, Taylor DW. The pathogenesis of chorioretinal disease in onchocerciasis. ACTA ACUST UNITED AC 2005; 13:94-8. [PMID: 15275111 DOI: 10.1016/s0169-4758(97)01005-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The pathogenesis of onchocercal chorioretinopathy is poorly understood. In this article, Philip Cooper, Ronald Guderian, Roberto Proaño and David Taylor discuss the important clinical, histological and epidemiological features of the resulting lesions that cause blindness, and review the numerous mechanisins that have been put forward to explain its pathogenesis. The pathogenesis of anterior segment disease, particulary sclerosing keratitis, has been reviewed in depth previously(1) and will not be discussed here.
Collapse
Affiliation(s)
- P J Cooper
- Laboratory of Parasitic Diseases, National Institutes of Health, Building 4, Room 126, Bethesda, MD 20892, USA.
| | | | | | | |
Collapse
|
3
|
Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996; 80:844-8. [PMID: 8962842 PMCID: PMC505625 DOI: 10.1136/bjo.80.9.844] [Citation(s) in RCA: 418] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|
4
|
Mabey D, Whitworth JA, Eckstein M, Gilbert C, Maude G, Downham M. The effects of multiple doses of ivermectin on ocular onchocerciasis. A six-year follow-up. Ophthalmology 1996; 103:1001-8. [PMID: 8684787 DOI: 10.1016/s0161-6420(96)30574-5] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND Ivermectin has been shown to be a safe treatment for onchocerciasis and is now being distributed through mass treatment programs. Previous studies of up to 3 years of treatment have demonstrated that ivermectin improves anterior segment lesions and reduces the incidence of optic atrophy. The benefit of multiple doses of ivermectin on visual acuity and chorioretinitis has yet to be shown. METHODS A community-based, double-blind, randomized, controlled trial of ivermectin was started in Bo, Sierra Leone, in 1987. Two cohorts are reported in this study: (1) 214 subjects had received four 6-month doses of ivermectin followed by up to six additional 6-month treatments. The second cohort, with 185 subjects, had received four 6-month doses of placebo followed by up to four annual doses of ivermectin. All subjects received a full ophthalmic examination in 1989 and again in 1994. For both cohorts, there was an 18-month gap between the fifth and sixth rounds of treatment. RESULTS There was no significant difference in the prevalences of any ocular lesion nor of visual acuity categories between the cohorts at the second examination. Comparisons of the prevalences of anterior segment lesions for both cohorts combined between the first and second examinations show highly significant improvement (P < 0.001) for all lesions. Posterior segment lesions show a more variable pattern, with chorioretinitis showing highly significant deterioration (P < 0.001) and the emergence of new lesions in both groups. CONCLUSION The authors conclude that annual treatment with ivermectin is effective in controlling ocular onchocerciasis apart from chorioretinal lesions and that a 6-month treatment gives no additional benefit.
Collapse
Affiliation(s)
- D Mabey
- Moorfields Eye Hospital, London, UK
| | | | | | | | | | | |
Collapse
|
5
|
Cooper PJ, Proaño R, Beltran C, Anselmi M, Guderian RH. Onchocerciasis in Ecuador: evolution of chorioretinopathy after amocarzine treatment. Br J Ophthalmol 1996; 80:337-42. [PMID: 8703886 PMCID: PMC505461 DOI: 10.1136/bjo.80.4.337] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
AIMS To investigate the impact of the macrofilaricidal drug, amocarzine, on the evolution of chorioretinopathy in onchocerciasis. METHODS A prospective uncontrolled cohort study was performed using subjects infected with Onchocerca volvulus in a hyperendemic onchocerciasis focus in Esmeraldas Province in Ecuador. Study subjects were recruited into four cohorts in which ophthalmic and parasitological data were collected for 2, 3, 4, and 5 years respectively. RESULTS Complete ophthalmic follow up was obtained for 294 individuals in the four cohorts. The incidence of retinal pigment epithelial atrophy tended to remain constant between cohorts while that of chorioretinal scarring with a greater observation period. The incidence rate of cases with new or extending chorioretinal lesions was greater with an increasing period of follow up. An association was seen between the cumulative microfilarial loads in the skin and the development of new chorioretinal lesions (p < 0.05). No relation was noted between cumulative microfilarial loads and the progression of existing disease. CONCLUSION Amocarzine therapy did not prevent the natural evolution of chorioretinal disease. It was suggested that ocular microfilariae were necessary for the induction of chorioretinopathy in previously unaffected eyes and that extension of existing disease might also be related to the presence of ocular microfilariae or to other immunological mechanisms.
Collapse
Affiliation(s)
- P J Cooper
- Onchocerciasis Control Programme, Hospital Vozandes, Quito, Ecuador
| | | | | | | | | |
Collapse
|
6
|
Cooper PJ, Proaño R, Beltran C, Anselmi M, Guderian RH. Onchocerciasis in Ecuador: changes in prevalence of ocular lesions in Onchocerca volvulus infected individuals over the period 1980-1990. Mem Inst Oswaldo Cruz 1996; 91:153-8. [PMID: 8736083 DOI: 10.1590/s0074-02761996000200004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Trends in prevalence rates of onchocercal ocular lesions were examined over the period 1980 to 1990 using data from two cross-sectional surveys. There was evidence for increasing prevalence of anterior chamber microfilariae, iridocyclitis, optic atrophy, and chorioretinopathy. Large increases in prevalence, in particular, were seen for posterior segment lesions: optic atrophy increased from 2.7% to 6.4% and chorioretinopathy from 8.8% to 35.6%. Greatest increases in these lesions were seen in the Chachi which was attributed to the large increases in prevalence of microfilariae in the anterior chamber particularly in those aged 30 years or greater. The study findings suggest that ocular onchocerciasis is evolving in parallel with the well documented parasitological changes.
Collapse
Affiliation(s)
- P J Cooper
- Onchocerciasis Control Programme, Hospital Vozandes, Quito, Ecuador
| | | | | | | | | |
Collapse
|
7
|
Ronday MJ, Stilma JS, Barbe RF, Kijlstra A, Rothova A. Blindness from uveitis in a hospital population in Sierra Leone. Br J Ophthalmol 1994; 78:690-3. [PMID: 7947548 PMCID: PMC504906 DOI: 10.1136/bjo.78.9.690] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
A retrospective study was conducted to assess the causes of blindness and visual impairment in patients who visited an eye hospital in Sierra Leone, West Africa, in 1989 and 1992. These data were compared with figures from 1981. Throughout the years, senile cataract was the major cause of blindness, followed by uveitis (including onchocerciasis). Uveitis remained the second most important cause of blindness in this population, despite the significant decrease in blindness from onchocerciasis (from 30% in 1981 to 15% in 1992). An increasing number of patients with uveitis from non-onchocercal origin was observed: almost 10% of the blindness found in 1992 was due to uveitis of non-onchocercal origin. A reduction in visual handicap in patients with non-onchocercal uveitis could be achieved if local hospitals could obtain more accurate diagnoses in these patients.
Collapse
Affiliation(s)
- M J Ronday
- Netherlands Ophthalmic Research Institute, Amsterdam
| | | | | | | | | |
Collapse
|
8
|
Murdoch I, Abiose A, Babalola O, Bird A, Cousens S, Evans J, Jones B. Ivermectin and onchocercal optic neuritis: short-term effects. Eye (Lond) 1994; 8 ( Pt 4):456-61. [PMID: 7821473 DOI: 10.1038/eye.1994.108] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
In 1982 the macrocyclic lactone, ivermectin, was first tested in human patients with onchocerciasis. It has since undergone phase I to IV trials and is now being widely distributed in onchocercal areas. The previous microfilaricide, diethylcarbamazine citrate (DEC), is known to precipitate or exacerbate active optic neuritis in some onchocercal patients, as part of a wider inflammatory response (the Mazzotti reaction). Ivermectin may also cause a mild reaction, especially in people with high microfilarial loads. Few data are available concerning the effect of ivermectin on active optic neuritis. A large, randomised, double-masked, phase IV trial is reported. Individuals were screened for evidence of optic nerve disease (OND), and those identified as possible cases of OND underwent detailed ophthalmic examination, including fluorescein angiography, before being dosed with ivermectin or placebo. A total of 6831 persons were screened of whom 856 (13%) underwent angiography prior to dosing. At 7-14 days after dosing an attempt was made to re-examine 50% of adults over the age of 20 years, including all those with OND. Six hundred and eighty-eight repeat or new angiograms were performed. During this period, 5 new cases of active optic neuritis and one case of exacerbation of existing optic neuritis were identified. Five of these individuals had received placebo and one ivermectin. Two individuals with optic neuritis before dosing had improved after 7-14 days. One had received placebo, the other ivermectin. Ivermectin does not appear to precipitate or exacerbate optic neuritis at a period of 7-14 days.
Collapse
Affiliation(s)
- I Murdoch
- Department of Ophthalmology, Ahmadu Bello University Teaching Hospital, Kaduna, Nigeria
| | | | | | | | | | | | | |
Collapse
|
9
|
Njoo FL, Stilma JS, van der Lelij A. Effects of repeated ivermectin treatment in onchocerciasis. Doc Ophthalmol 1992; 79:261-7. [PMID: 1600843 DOI: 10.1007/bf00158256] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
A group of 87 onchocerciasis patients from a hyperendemic area without vector control was treated with a single dose of 150 micrograms/kg ivermectin. A second, third and fourth dose was administered 5, 12 and 17 months later to 44, 35 and 25 patients. Skin snip loads reduced substantially following each consecutive dose. However, after three doses 44% of the patients remained skin snip positive. Side-effects decreased from 32.2% requiring medical treatment at the first dose to none after the fourth dose. From this study it was concluded that a complete eradication of microfilariae in skin snips in severely infected persons living in a hyperendemic area without vector control is probably not feasible. Medical supervision for the observation of side-effects after the third dose can be limited.
Collapse
Affiliation(s)
- F L Njoo
- The Netherlands Ophthalmic Research Institute, Department of Ophthalmo-Immunology, Amsterdam
| | | | | |
Collapse
|
10
|
Whitworth JA, Gilbert CE, Mabey DM, Maude GH, Morgan D, Taylor DW. Effects of repeated doses of ivermectin on ocular onchocerciasis: community-based trial in Sierra Leone. Lancet 1991; 338:1100-3. [PMID: 1682543 DOI: 10.1016/0140-6736(91)91963-u] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Ivermectin seems to be a safe and effective treatment for onchocerciasis when given in a single dose, but less is known about the effects of repeated doses. Also, there seem to be differences in its effectiveness in anterior and posterior segment ocular disease. The ocular effects of ivermectin were studied in 586 villagers who were taking part in a double-blind, placebo-controlled, randomised trial in Sierra Leone. Only those who had received four doses, with 6-month intervals, of ivermectin or placebo were eligible. The 296 ivermectin-treated subjects and the 272 who received placebo were comparable with respect to age, sex, Onchocerca infection, blindness, and visual impairment before treatment. After treatment, the ivermectin group had less anterior segment disease than the placebo group, with significantly lower prevalences of microfilariae in the anterior chamber and cornea, and punctate keratitis (all p less than 0.001), and iritis (p less than 0.05). There was no significant difference in the prevalence of sclerosing keratitis, optic atrophy, or chorioretinitis between the groups. Visual acuities tended to be better in the ivermectin group, but the difference was not significant. There was a small but significant (p less than 0.01) excess of vascular sheathing in the ivermectin group. These differences persisted when subjects who were blind or visually impaired at baseline were excluded from analysis. The long-term effects of ivermectin, particularly on posterior segment disease, need further evaluation. In the mean time, the mass distribution of ivermectin should be promoted for all communities with hyperendemic onchocerciasis at risk of anterior segment disease.
Collapse
Affiliation(s)
- J A Whitworth
- Medical Research Council Laboratory, Bo, Sierra Leone
| | | | | | | | | | | |
Collapse
|
11
|
Stilma JS, Franken S, Hogeweg M, Hardus P. Points of action in the campaign against blindness in developing countries. Doc Ophthalmol 1991; 78:285-305. [PMID: 1790753 DOI: 10.1007/bf00165693] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
This article provides a survey of the problems of prevention of blindness in developing countries. The World Health Organization estimates that 31 million people are blind and 15 million people partially-sighted. The main cause of blindness is cataract. Other causes are trachoma, glaucoma, xerophthalmia, river blindness, corneal scars and leprosy. Prevention or treatment of these causes is possible in more than 80% of cases. The number of blind persons, however, is still increasing due to the increase in population and the immense shortage of all kinds of ophthalmological equipment and personnel. An effective strategy for the prevention of blindness in developing countries should focus on: more cheap cataract operations, increasing teaching facilities for ophthalmic personnel, integration of ophthalmic care into the general health system and the promotion of blindness prevention in political organizations.
Collapse
Affiliation(s)
- J S Stilma
- F.C. Dondersinstitute, Utrecht, The Netherlands
| | | | | | | |
Collapse
|
12
|
Van der Lelij A, Rothova A, Klaassen-Broekema N, Wilson WR, Barbe RF, Stilma JS. Decrease in adverse reactions after repeated ivermectin treatment in onchocerciasis. Doc Ophthalmol 1990; 75:215-24. [PMID: 2090395 DOI: 10.1007/bf00164834] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
We assessed the side-effects after multiple single-dose treatment with ivermectin (150 micrograms/kg) in onchocerciasis patients form a hyperendemic area in Sierra Leone, in order to investigate whether medical surveillance was always necessary. After initial treatment 87 onchocerciasis patients were examined for adverse reactions. Fourty-four of these 87 patients (51%) received a second dose of ivermectin 5 months later and thirty-five (40%) received a third dose one year later. The side-effects after the second and third doses were significantly diminished, when compared with the initial dose of ivermectin in the treatment of onchocerciasis (chi2 test p less than 0.005, resp. p less than 0.008). Side-effects requiring therapy were observed in 32% of patients after the first dose, in 18% after the second dose and in 11% after the third dose of ivermectin. Severe side-effects (9%) were only seen after the initial ivermectin dose. All the severe adverse reactions appeared within 48 hours. In view of our findings, it seems necessary that the first treatment with ivermectin should take place under strict medical supervision during at least two days. Five months after treatment with a single dose of ivermectin 29 out of 44 patients (66%) still had a positive skin-snip test. Seven months after the second dose 15 of 35 patients (43%) had a positive skin-snip count. Since almost half of the patients had a positive skin-snip test despite two treatments with ivermectin, it could be argued that in hyperendemic areas treatment should consist of at least two doses in the first year.
Collapse
Affiliation(s)
- A Van der Lelij
- Department of Ophthalmology, Free University Amsterdam, The Netherlands
| | | | | | | | | | | |
Collapse
|